newsfilter
← Earnings
Earnings Releases·

LENSAR — Third Quarter 2026 Earnings Summary

  • Total revenue declined 1% year-over-year to $14.1 million, driven by lower system sales, while recurring revenue grew 17% to $12.6 million (89% of total revenue) and procedure volume rose 12% to 52,545.
  • Net loss widened to $4.7 million from $3.7 million in the prior year period, though Adjusted EBITDA improved to a positive $1.7 million compared to a $0.3 million loss previously.
  • The ALLY installed base expanded 22% year-over-year to approximately 225 systems with 12 units in backlog, despite system sales revenue falling to $1.5 million from $3.5 million.
  • Management attributed the revenue dip to typical summer seasonality and a robust prior-year base, reaffirming a focus on long-term growth through the expanding installed base and disciplined commercial execution.
Company
LENSAR INC
Sector
Healthcare
Industry
Medical Devices